The biology and therapeutic potential of interleukin 27

[1]  A. Yoshimura,et al.  Two-Sided Roles of IL-27: Induction of Th1 Differentiation on Naive CD4+ T Cells versus Suppression of Proinflammatory Cytokine Production Including IL-23-Induced IL-17 on Activated CD4+ T Cells Partially Through STAT3-Dependent Mechanism1 , 2006, The Journal of Immunology.

[2]  S. Ehlers,et al.  Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. , 2006, Immunobiology.

[3]  L. Hennighausen,et al.  Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system , 2006, Nature Immunology.

[4]  R. Kastelein,et al.  Differential effects of IL-27 on human B cell subsets , 2006, The Journal of Immunology.

[5]  D. Danilenko,et al.  Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17–producing T cells , 2006, Nature Immunology.

[6]  H. Schild,et al.  Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27 , 2006, The Journal of experimental medicine.

[7]  S. Swain,et al.  Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection , 2006, The Journal of experimental medicine.

[8]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[9]  H. Nagai,et al.  Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. , 2006, Cancer research.

[10]  M. Kudo,et al.  Antiangiogenic and Antitumor Activities of IL-271 , 2006, The Journal of Immunology.

[11]  L. Hennighausen,et al.  Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Peng.  The T-box transcription factor T-bet in immunity and autoimmunity. , 2006, Cellular & molecular immunology.

[13]  K. Takeda,et al.  IL-27 Suppresses CD28-Medicated IL-2 Production through Suppressor of Cytokine Signaling 31 , 2006, The Journal of Immunology.

[14]  S. Sakaguchi,et al.  The dichotomous role of IL-2: tolerance versus immunity. , 2006, Trends in immunology.

[15]  R. Kastelein,et al.  IL-27 Limits IL-2 Production during Th1 Differentiation1 , 2006, The Journal of Immunology.

[16]  H. Hirakata,et al.  Membranous Glomerulonephritis Development with Th2-Type Immune Deviations in MRL/lpr Mice Deficient for IL-27 Receptor (WSX-1)1 , 2005, The Journal of Immunology.

[17]  H. Nawata,et al.  T Helper 1‐Inducing Property of II‐27/WSX‐1 Signaling Is Required for the Induction of Experimental Colitis , 2005, Inflammatory bowel diseases.

[18]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[19]  A. Yoshimura,et al.  Exacerbation of Experimental Allergic Asthma by Augmented Th2 Responses in WSX-1-Deficient Mice1 , 2005, The Journal of Immunology.

[20]  T. Yoshimoto,et al.  Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27 1 , 2005, The Journal of Immunology.

[21]  M. Tagawa,et al.  Expression of IL‐27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals , 2005, International journal of cancer.

[22]  S. Finotto,et al.  Pathological role of IL-6 in the experimental allergic bronchial asthma in mice , 2005, Clinical reviews in allergy & immunology.

[23]  M. Freudenberg,et al.  IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. , 2005, International immunology.

[24]  C. Hölscher.  Targeting IL-23 in autoimmunity. , 2005, Current opinion in investigational drugs.

[25]  A. Suzumura,et al.  Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations , 2005, Brain Research.

[26]  M. Neurath,et al.  Impaired Th1 responses in mice deficient in Epstein‐Barr virus‐induced gene 3 and challenged with physiological doses of Leishmania major , 2005, European journal of immunology.

[27]  T. Mak,et al.  The IL-27 Receptor Chain WSX-1 Differentially Regulates Antibacterial Immunity and Survival during Experimental Tuberculosis 1 , 2005, The Journal of Immunology.

[28]  H. Schild,et al.  EBV-Induced Gene 3 Transcription Is Induced by TLR Signaling in Primary Dendritic Cells via NF-κB Activation , 2005, The Journal of Immunology.

[29]  J. Cebon,et al.  Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. , 2005, Blood.

[30]  J. Scheller,et al.  No inhibition of IL-27 signaling by soluble gp130. , 2005, Biochemical and biophysical research communications.

[31]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[32]  J. Schwartzman,et al.  Interleukin-17/Interleukin-17 Receptor-Mediated Signaling Is Important for Generation of an Optimal Polymorphonuclear Response against Toxoplasma gondii Infection , 2005, Infection and Immunity.

[33]  S. Khader,et al.  IL-27 Signaling Compromises Control of Bacterial Growth in Mycobacteria-Infected Mice1 , 2004, The Journal of Immunology.

[34]  R. Kastelein,et al.  IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells1 , 2004, The Journal of Immunology.

[35]  Y. Zohar,et al.  Suppression of Ongoing Experimental Autoimmune Encephalomyelitis by Neutralizing the Function of the p28 Subunit of IL-271 , 2004, The Journal of Immunology.

[36]  G. Wu,et al.  The IL-27 Receptor (WSX-1) Is an Inhibitor of Innate and Adaptive Elements of Type 2 Immunity1 , 2004, The Journal of Immunology.

[37]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[38]  T. Yoshimoto,et al.  An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells1 , 2004, The Journal of Immunology.

[39]  F. Lemonnier,et al.  Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice , 2004, Journal of Virology.

[40]  Y. Iwakura,et al.  Induction of IgG2a Class Switching in B Cells by IL-271 , 2004, The Journal of Immunology.

[41]  Y. Zohar,et al.  Suppression of Ongoing Adjuvant-Induced Arthritis by Neutralizing the Function of the p28 Subunit of IL-27 , 2004, The Journal of Immunology.

[42]  M. Kagnoff,et al.  Expression of Epstein–Barr virus‐induced gene 3 and other interleukin‐12‐related molecules by human intestinal epithelium , 2004, Immunology.

[43]  R. Grencis,et al.  WSX-1: A Key Role in Induction of Chronic Intestinal Nematode Infection1 , 2004, The Journal of Immunology.

[44]  C. Hunter,et al.  Cutting Edge: Early IL-4 Production Governs the Requirement for IL-27-WSX-1 Signaling in the Development of Protective Th1 Cytokine Responses following Leishmania major Infection1 , 2004, The Journal of Immunology.

[45]  T. Mak,et al.  Hyperproduction of Proinflammatory Cytokines by WSX-1-Deficient NKT Cells in Concanavalin A-Induced Hepatitis1 , 2004, The Journal of Immunology.

[46]  T. Mcclanahan,et al.  WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27 , 2004, The Journal of Immunology.

[47]  Maria Laura Belladonna,et al.  Potent Antitumor Activity of Interleukin-27 , 2004, Cancer Research.

[48]  N. Brousse,et al.  Expression of IL‐27 in human Th1‐associated granulomatous diseases , 2004, The Journal of pathology.

[49]  L. Joosten,et al.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. , 2004, Arthritis and rheumatism.

[50]  C. Hunter,et al.  STAT1 Plays a Critical Role in the Regulation of Antimicrobial Effector Mechanisms, but Not in the Development of Th1-Type Responses during Toxoplasmosis1 , 2004, The Journal of Immunology.

[51]  S. Szabo,et al.  Antigen-driven effector CD8 T cell function regulated by T-bet , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  F. D. de Sauvage,et al.  IL-27 regulates IL-12 responsiveness of naïve CD4+ T cells through Stat1-dependent and -independent mechanisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Nakae,et al.  Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.

[54]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.

[55]  T. Mak,et al.  WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. , 2003, Immunity.

[56]  T. Mak,et al.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. , 2003, Immunity.

[57]  R. Kastelein,et al.  IL-27 and IFN-α Signal via Stat1 and Stat3 and Induce T-Bet and IL-12Rβ2 in Naive T Cells , 2003 .

[58]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[59]  Massimo Gadina,et al.  Cytokines and Transcription Factors That Regulate T Helper Cell Differentiation: New Players and New Insights , 2003, Journal of Clinical Immunology.

[60]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[61]  J. Gratama,et al.  IL-12: a promising adjuvant for cancer vaccination , 2003, Cancer Immunology, Immunotherapy.

[62]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[63]  M. Neurath,et al.  Disruption of T helper 2-immune responses in Epstein–Barr virus-induced gene 3-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[65]  J. Kohlmeier,et al.  Stimulation Through Intercellular Adhesion Molecule-1 Provides a Second Signal for T Cell Activation , 2002, The Journal of Immunology.

[66]  Wenda Gao,et al.  Interleukin-6 is required for parasite specific response and host resistance to Trypanosoma cruzi. , 2002, International journal for parasitology.

[67]  A. Sher,et al.  T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  T. Mak,et al.  WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. , 2001, Immunity.

[69]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[70]  F.J. Sauvage,et al.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR , 2000, Nature.

[71]  B. Hilliard,et al.  IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. , 1998, Journal of immunology.

[72]  Scott R. Presnell,et al.  Cloning and characterization of a novel class I cytokine receptor. , 1998, Biochemical and biophysical research communications.

[73]  C. Roberts,et al.  A protective role for IL‐6 during early infection with Toxoplasma gondii , 1998, Parasite immunology.

[74]  E. Kieff,et al.  Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Y. Suzuki,et al.  Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice , 1997, Infection and immunity.

[76]  J. Norton,et al.  IL-12 induces T helper 1-directed antitumor response. , 1997, Journal of immunology.

[77]  H. Fujiwara,et al.  Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor growth inhibition induced during tumor immunotherapy with rIL-12 , 1996 .

[78]  E. Kieff,et al.  A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes , 1996, Journal of virology.

[79]  H. Fujiwara,et al.  Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. , 1995, International immunology.

[80]  C. Hunter,et al.  Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. , 2006, The American journal of pathology.

[81]  B. Jenkins,et al.  Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.

[82]  武田 篤信.  Cutting edge : Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment , 2003 .

[83]  A. Sher,et al.  T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[84]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[85]  H. Fujiwara,et al.  Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. , 1996, International immunology.